Voltar
Artigo Revisado por pares
BIBTEX RIS

Tumor‐Necrosis‐Factor Blockers: Differential Effects on Mycobacterial Immunity

2006; Oxford University Press; Volume: 194; Issue: 4 Linguagem: Inglês

10.1086/505430

ISSN

1537-6613

Autores

Oluwabunmi Y. Saliu, Carolina Sofer, Dana Stein, Stephan Schwander, Robert S. Wallis,

Tópico(s)

Infectious Diseases and Tuberculosis

Resumo

BackgroundTumor necrosis factor (TNF) plays a pathogenic role in rheumatoid arthritis but is essential for antimycobacterial host defenses. The risk of reactivation of latent Mycobacterium tuberculosis infection is greater with the TNF monoclonal antibody infliximab than with the soluble TNF receptor etanercept. The basis of this difference is not known

Referência(s)